Nasdaq:US$15.45 (+0.40) | HKEX:HK$23.55 (-0.20) | AIM:£2.23 (-0.04)
搜索
新闻档案

通过选择所需的新闻类型，可以获得最新的公告或演示文稿。

请使用 「新闻主题」进一步挑选公告类别。
 

所有公告的全文可以PDF文件的形式下载。为方便起见，某些公告的部分或全部文字内容以网页的方式呈现。如存有任何不一致之处，请以PDF版本为准。

新闻类型
公告及新闻稿
演示文稿
新闻主题
其他业务
监管通知
肿瘤学 / 免疫学
集团
12345678910
11
121314151617
找到相关结果： 823
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-06-29

和黄医药与阿斯利康联手启动沃利替尼治疗乳头状肾细胞癌的全球III期临床试验“SAVOIR”
阿斯利康制药（“阿斯利康”） (LON/STO/NYSE: AZN) 和黄中国医药科技有限公司 （简称 “和黄医药”） （纳斯达克/伦敦证交所：HCM）   2017年6月29日： 和黄医药今日宣布将
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2017-06-29

Blocklisting Six Monthly Return
London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limited 2. Name of sc
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-06-29

Chi-Med to Announce 2017 Half-Year Financial Results
London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time (BST). An ana
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-06-22

和黄医药在中国启动新型FGFR抑制剂HMPL 453的I/II期临床试验
2017年6月22日：和黄医药近日在中国启动HMPL-453的I/II期临床试验。HMPL-453是一种靶向成纤维细胞生长因子受体（FGFR）的新型高选择性小分子抑制剂。2017年6月19日首位受试者接受给药治疗。该
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2017-06-16

Director’s Share Dealing
London: Friday, June 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Dynamic Drive Limited, a person closely associated (“PCA”) with Mr Simon To, Executive Director and Chairma
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-06-12

和黄医药向国家食品药品监督管理局递交呋喹替尼治疗晚期结直肠癌的新药上市申请
  –国家食品药品监督管理局已受理申请，并将由 药品审评中心作技术审核– –将收到来自礼来共计3080万人民币的里程碑付款–   2017年6月12日：和黄医药今日宣布药物呋喹替尼
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-06-05

和黄医药在ASCO年会上就呋喹替尼临床III期研究数据进行口头报告
2017年6月5日：和黄医药宣布在今天于美国芝加哥举行的美国临床肿瘤学会（ASCO）年会上就其自主研发的高选择性血管细胞内皮生长因子受体（VEGFR）抑制剂的关键III期临床研究结果进行了口
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-05-18

和黄医药在ASCO 2017年会上公布临床数据
  – 受ASCO组委会邀请口头报告呋喹替尼治疗结直肠癌的III期临床研究“FRESCO”的研究结果 –   –将在大会上展示呋喹替尼，沃利替尼和索凡替尼共5项研究摘要 –   2017年5月18
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2017-04-28

Total Voting Rights
London: Friday, April 28, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 28, 2017, the issued share capital of Chi-Med consisted of 60,735,104 ordinary sh
阅读更多
公告及新闻稿, 监管通知 | 2017-04-27

Results of Annual General Meeting
London: Thursday, April 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2017 were duly
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-04-07

和黄医药在2017年AACR年会上公布呋喹替尼和索凡替尼的临床前数据
2017年4月7日：和黄医药在2017年4月1日至5日于美国华盛顿举行的美国癌症研究协会(AACR)年会上公布了呋喹替尼和索凡替尼的临床前数据。呋喹替尼和索凡替尼目前都在以多种癌症为适应症的III
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2017-03-31

Total Voting Rights
London: Friday, March 31, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2017, the issued share capital of Chi-Med consisted of 60,715,323 ordinary sh
阅读更多
公告及新闻稿, 监管通知 | 2017-03-29

Vesting of awards under the Long Term Incentive Plan
公告及新闻稿, 监管通知 | 2017-03-28

Grant of Share Options under Share Option Scheme
London: Tuesday, March 28, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 27, 2017, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,
阅读更多
公告及新闻稿, 集团 | 2017-03-27

2016 Annual Report and Notice of Annual General Meeting
London: Monday, March 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2016 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-03-24

Chi-Med Appoints Weiguo Su, Chief Scientific Officer, to Board of Directors
Appointment of Director London: Friday, March 24, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as Executive Director and member of Technical Commi
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-03-21

Chi-Med to host R&D Briefings on March 29 & 30, 2017
Press Release London: Tuesday, March 21, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it will host Research & Development (“R&D”) briefings in London and New York to provide an overview o
阅读更多
公告及新闻稿, 监管通知 | 2017-03-20

Directors’ Share Dealing
London: Monday, March 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Mr Paul Carter, Independent Non-executive Director, purchased a total of 2,800 ordinary shares of US$1.00 each in
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-03-16

Grant of Awards under Long Term Incentive Plan
Press Release London: Thursday, March 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan (“LTIP”) a
阅读更多
公告及新闻稿, 集团 | 2017-03-13

Publication of Form 20-F for the Year Ended December 31, 2016
London: Monday, March 13, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2016 per attached and also available for viewing on the Company's website at ww
阅读更多
公告及新闻稿, 集团 | 2017-03-13

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs
Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and clinical investment in 2016 Group revenue up 21%
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-03-10

和黄医药在欧洲神经内分泌肿瘤学会年会上公布索凡替尼治疗神经内分泌瘤Ib/II期临床试验结果
2017年3月10日：和黄医药在2017年3月8日至10日于西班牙巴塞罗那举行的第14届欧洲神经内分泌肿瘤学会年会（ENETS）上公布了索凡替尼正在进行的治疗晚期神经内分泌瘤的Ib/II期临床试验结果。
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 肿瘤学 / 免疫学 | 2017-03-03

和黄医药宣布呋喹替尼（HMPL-013）以局部晚期或转移性结直肠癌为适应症的III期临床试验“FRESCO”取得成功
  –达到首要和次要终点 – – 安全性及疗效达到预期 – –计划于2017年中递交中国新药上市申请– –完整详细的试验结果将在2017年中通过肿瘤学术大会公布–   2017年3月3日：
阅读更多
查看公告 (PDF)
公告及新闻稿, 新闻稿, 集团 | 2017-02-28

Chi-Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee
Change of Directors London: Tuesday, February 28, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:- Mr Graeme Allan Jack has been appointed as I
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-02-20

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma
Press Release London: Monday, February 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally advanced or metastatic pulmonary sarcomatoid carci
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-02-14

Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia
London: Tuesday, February 14, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated the first-in-human (“FIH”) Phase I clinical trial of HMPL-453 in Australia.  HMPL-453 is a novel, highly
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-02-14

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium
Press Release London: Tuesday, February 14, 2017:  Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) and AstraZeneca PLC (“AstraZeneca”) will present data from the ongoing Phase II clinical trial of savolitinib in patients wi
阅读更多
公告及新闻稿, 监管通知 | 2017-02-06

Chi-Med to Announce 2016 Final Results
London: Monday, February 6, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2016 on Monday, March 13, 2017 at 7:00 am Greenwich Mean Time (GMT). An analy
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-02-01

Chi-Med Appoints Industry Veteran Karen Ferrante to Board of Directors
Change of Directors London: Wednesday, February 1, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that with effect from today:- Dr Karen Jean Ferrante has been appointed as Independent Non-Executive Director
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-01-16

Chi-Med Appoints Industry Veteran Paul Carter to Board of Directors
Change of Directors London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Execut
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-16

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer
London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq:HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa® in the first-line setting for patients
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-16

Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China
London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of sulfatinib in second-line biliary tract cancer (“BTC”) patients in China.  Sulfatinib
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-16

Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium
London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from the ongoing Phase I/II clinical trial of fruquintinib in combination with paclitaxel (Taxol®) in second-line patients
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-10

Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China
London: Tuesday, January 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase (“Syk”) inhibitor, HMPL-523, in patients with hematolo
阅读更多
公告及新闻稿, 监管通知 | 2016-12-30

Total Voting Rights
London: Friday, December 30, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 30, 2016, the issued share capital of Chi-Med consisted of 60,705,823 ordin
阅读更多
公告及新闻稿, 监管通知 | 2016-12-29

Blocklisting Six Monthly Return
London: Thursday, December 29, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutchis
阅读更多
公告及新闻稿, 监管通知 | 2016-12-20

Director’s Share Dealing
London: Tuesday, December 20, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: CM) has received notification that Mr Simon To, Executive Director and Chairman, purchased a total of 17,839 American Depositary Shares of the Company (
阅读更多
公告及新闻稿, 监管通知 | 2016-12-14

Director’s Share Dealing
London: Wednesday, December 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Simon To, executive Director and Chairman, purchased a total of 52,161 American Depositary Shares of the Compan
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-12-06

Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting
Press Release London: Tuesday, December 6, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent pre-clinical study, investigating the in vitro and in vivo anti-tumor activities of novel Spl
阅读更多
公告及新闻稿, 监管通知 | 2016-11-30

Exercise of Share Options by a Person Discharging Managerial Responsibilities
London: Wednesday, November 30, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being a Person Discharging Managerial Respons
阅读更多
公告及新闻稿, 监管通知 | 2016-11-30

Total Voting Rights
London: Wednesday, November 30, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2016, the issued share capital of Chi-Med consisted of 60,703,323 or
阅读更多
公告及新闻稿, 监管通知 | 2016-11-23

Director’s Share Dealing
London: Wednesday, November 23, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-11-23

Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)
Press Release London: Wednesday, November 23, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that results from two non-small cell lung cancer (“NSCLC”) clinical studies will be presented at WCLC in Vienn
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-11-14

Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting
Press Release London: Monday, November 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokineti
阅读更多
公告及新闻稿, 监管通知 | 2016-11-01

Director's Share Dealing
London: Tuesday, November 1, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the
阅读更多
公告及新闻稿, 其他业务, 新闻稿 | 2016-10-31

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment
Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 Shanghai factory relocation complete: now operational with three-fold increase in capacity Cash from Chi-Med Commercial Platform supports developmen
阅读更多
公告及新闻稿, 监管通知 | 2016-10-12

Director's Share Dealing
London: Wednesday, October 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sold 15,000 ordinary shares of US$1.00 each in Chi-Med (
阅读更多
公告及新闻稿, 监管通知 | 2016-08-09

Director's Share Dealing
London: Tuesday, August 9, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US
阅读更多
公告及新闻稿, 集团 | 2016-08-02

Change of Non-executive Directors
London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha
阅读更多
公告及新闻稿, 集团 | 2016-08-02

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs
Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment.   Innovation Platform – Seven drug candidates in 25
阅读更多
12345678910
11
121314151617